Mammalian Target of Rapamycin as a Target in Hematological Malignancies

Isam A. Abdel-Karim; Francis J. Giles

doi:10.1016/j.currproblcancer.2008.05.001

Mammalian Target of Rapamycin as a Target in Hematological Malignancies

Isam A. Abdel-Karim^*, Francis J. Giles

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Despite significant advances in the treatment of hematological malignancies over the previous decades, morbidity and mortality from theses disorders still remain high. New discoveries in the pathways involved in the pathophysiology led to new thinking in drug discovery. mTOR inhibitors are new and viable options for patients with these malignancies. We hope that newer clinical data will bring about new options in this field.

Original language	English (US)
Pages (from-to)	161-177
Number of pages	17
Journal	Current Problems in Cancer
Volume	32
Issue number	4
DOIs	https://doi.org/10.1016/j.currproblcancer.2008.05.001
State	Published - Jul 1 2008

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.currproblcancer.2008.05.001

Cite this

@article{e543375c9430432ca7dc08cca0e0d428,

title = "Mammalian Target of Rapamycin as a Target in Hematological Malignancies",

abstract = "Despite significant advances in the treatment of hematological malignancies over the previous decades, morbidity and mortality from theses disorders still remain high. New discoveries in the pathways involved in the pathophysiology led to new thinking in drug discovery. mTOR inhibitors are new and viable options for patients with these malignancies. We hope that newer clinical data will bring about new options in this field.",

author = "Abdel-Karim, {Isam A.} and Giles, {Francis J.}",

year = "2008",

month = jul,

day = "1",

doi = "10.1016/j.currproblcancer.2008.05.001",

language = "English (US)",

volume = "32",

pages = "161--177",

journal = "Current Problems in Cancer",

issn = "0147-0272",

publisher = "Mosby Inc.",

number = "4",

}

TY - JOUR

T1 - Mammalian Target of Rapamycin as a Target in Hematological Malignancies

AU - Abdel-Karim, Isam A.

AU - Giles, Francis J.

PY - 2008/7/1

Y1 - 2008/7/1

N2 - Despite significant advances in the treatment of hematological malignancies over the previous decades, morbidity and mortality from theses disorders still remain high. New discoveries in the pathways involved in the pathophysiology led to new thinking in drug discovery. mTOR inhibitors are new and viable options for patients with these malignancies. We hope that newer clinical data will bring about new options in this field.

AB - Despite significant advances in the treatment of hematological malignancies over the previous decades, morbidity and mortality from theses disorders still remain high. New discoveries in the pathways involved in the pathophysiology led to new thinking in drug discovery. mTOR inhibitors are new and viable options for patients with these malignancies. We hope that newer clinical data will bring about new options in this field.

UR - http://www.scopus.com/inward/record.url?scp=48949119272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48949119272&partnerID=8YFLogxK

U2 - 10.1016/j.currproblcancer.2008.05.001

DO - 10.1016/j.currproblcancer.2008.05.001

M3 - Article

C2 - 18655914

AN - SCOPUS:48949119272

SN - 0147-0272

VL - 32

SP - 161

EP - 177

JO - Current Problems in Cancer

JF - Current Problems in Cancer

IS - 4

ER -

Mammalian Target of Rapamycin as a Target in Hematological Malignancies

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this